Topvision Eye Specialist Berhad (0332) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Topvision Eye Specialist Berhad stock MYR 0.15, price MYR 0.17, that is 11.8% below the price, quality 45 out of 100. Rating: overvalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range 0.1500 MYR – 0.6806 MYR · fair‑value band 0.0900 MYR – 0.2200 MYR · the 0.1700 MYR price screens above the 0.1500 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Topvision Eye Specialist Berhad in your weekly email
Every Wednesday you see whether Topvision Eye Specialist Berhad is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Topvision Eye Specialist Berhad, together with its subsidiaries, provides ophthalmology healthcare services in Malaysia.
Show moreShow less
The company offers various eye care services for cataract, diabetic retinopathy, retinal detachment, glaucoma, age-related macular degeneration, pterygium, children's eye disorder, and other eye problems, including cornea ulcer, dry eyes, eyelid abscess, foreign body removal, subconjunctival hemorrhage, trauma, and viral conjunctivitis.
It also engages in the provision of related medical consultancy services; marketing of eye supplements and health food products; retail sale of food and beverage; and import, export, and distribution of pharmaceuticals, medical devices and goods, cosmetics, and health supplements.
The company was founded in 2010 and is headquartered in Shah Alam, Malaysia.
Stock analysis
Topvision Eye Specialist Berhad (0332) currently trades at 0.1700 MYR, while our model-based Fair Value estimate is 0.1500 MYR, 12% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of 0.2700 MYR per share, and 10 of the 25 models we run sit above the 0.1700 MYR price.
Bear case: the Asset-Based group reads lowest at 0.0900 MYR, and 15 of the 25 models stay below the price. Data coverage for this calculation is low.
Scenario range: 0.0900 MYR (bear) to 0.2200 MYR (bull), the price of 0.1700 MYR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Topvision Eye Specialist Berhad reported revenue of 45.8M MYR in FY2025 versus 39.5M MYR in FY2022, a compound +5.1%/yr. Reported net income was 2.0M MYR in FY2025, compounding −31.2%/yr from FY2022.
Key figures
Market cap 52.7M MYR (≈ $13.0M) Micro · P/E ratio 17.0 · P/S ratio 1.11 · EPS (TTM) 0.0100 MYR · Dividend yield 11.8% · Net margin 4.8% · Return on equity 5.2% · Return on assets (EBIT) 12.2% (4-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and 13% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −12%, 0332 screens richer than that median.
Fair Value models
Bear0.0900 MYRFair Value 0.1500 MYRBull0.2200 MYR
Price 0.1700 MYR · Downside -11.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.64/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+3.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−21.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−33.0%
Dividend (yield on the price)11.8%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 11%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+22.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Malaysia: IMF forecast 2.0% a year to 2030, 1.8% from 2016 to 2025) that is about +20.3% a year for the price.
Compare Topvision Eye Specialist Berhad with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score45 · Bottom 25%
Fair Value upside−11.8% · Below median
Profitability
Return on equity (12 months)5.2% · Below median
Return on assets2.6% · Below median
Net margin (12 months)4.8% · Below median
Operating margin (12 months)20.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)15.6% · Top 25%
Dividend yield (12 months)11.8% · Top 25%
Balance sheet
Debt / equity0.25× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Topvision Eye Specialist Berhad (0332) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 0.1500 MYR versus a price of 0.1700 MYR, about 12% lower (overvalued).
What is the fair value of 0332?
Our model-based fair value for Topvision Eye Specialist Berhad is 0.1500 MYR (as of Nov 4, 2026), built from audited fundamentals. The current price: 0.1700 MYR.
What is the quality score of 0332?
Topvision Eye Specialist Berhad has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Topvision Eye Specialist Berhad (0332)?
Our model-based price target is the fair value of 0.1500 MYR (as of Nov 4, 2026) from 25 valuation models. Cautious scenario 0.0900 MYR, optimistic scenario 0.2200 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the Topvision Eye Specialist Berhad stock forecast for 2026?
Our models put fair value at 0.1500 MYR, about 12% lower versus a price of 0.1700 MYR (overvalued). Cautious scenario 0.0900 MYR, optimistic scenario 0.2200 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of Topvision Eye Specialist Berhad (0332)?
Topvision Eye Specialist Berhad reported trailing-twelve-month revenue of about 47.4M MYR (latest available figure, as of Nov 4, 2026).
Does Topvision Eye Specialist Berhad pay a dividend?
Topvision Eye Specialist Berhad currently shows a dividend yield of 11.76% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of Topvision Eye Specialist Berhad (0332) and when is the ex-dividend date?
Topvision Eye Specialist Berhad pays a dividend of 0.02 MYR per share a year, a dividend yield of 11.8%. The last ex-dividend date was Sep 14, 2026. The payout ratio is 200% of earnings. Free cash flow covers the dividend 0.21 times. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What growth is priced into Topvision Eye Specialist Berhad (0332)?
For today's price to be fair in a discounted-cash-flow model, Topvision Eye Specialist Berhad would have to grow free cash flow by +22.7 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +5.1 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of 0332 use?
Our models discount Topvision Eye Specialist Berhad at 9.7 %: a base by market capitalisation (nano), damped by beta 0.01, country premium for Malaysia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Topvision Eye Specialist Berhad that is +22.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Topvision Eye Specialist Berhad (0332) delivered so far?
Over the past 3 years revenue at Topvision Eye Specialist Berhad grew +5.1 % a year. The price currently implies free-cash-flow growth of +22.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Topvision Eye Specialist Berhad (0332) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Topvision Eye Specialist Berhad (+22.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Topvision Eye Specialist Berhad (0332)?
The free-cash-flow yield on the price is 2.52 %: that much free cash flow Topvision Eye Specialist Berhad produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Topvision Eye Specialist Berhad (0332)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Topvision Eye Specialist Berhad it is 0.1500 MYR per share (as of Nov 4, 2026), against a price of 0.1700 MYR. It is the blended result of 25 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Topvision Eye Specialist Berhad stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 0332 trades above its calculated fair value: price 0.1700 MYR, fair value 0.1500 MYR, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0332?
No. The price is what the market pays today (0.1700 MYR); the fair value is what the company's own numbers justify (0.1500 MYR). For Topvision Eye Specialist Berhad the two are 0.0200 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is Topvision Eye Specialist Berhad worth?
The market values Topvision Eye Specialist Berhad at about 52.7M MYR (market capitalisation, as of Nov 4, 2026). Per share that is 0.1700 MYR; our models calculate a fair value of 0.1500 MYR per share.
What do the bullish and bearish scenarios say about 0332?
Our models span a range for Topvision Eye Specialist Berhad: cautious scenario 0.0900 MYR, base 0.1500 MYR, optimistic 0.2200 MYR per share (as of Nov 4, 2026, price 0.1700 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0332?
Topvision Eye Specialist Berhad trades at a price-to-earnings ratio of 17.0 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.1500 MYR is built from several models across several years. Other multiples: P/B 1.2, P/S 1.1, EV/EBITDA 5.1.
How solid is the balance sheet of Topvision Eye Specialist Berhad (0332)?
Balance-sheet figures for Topvision Eye Specialist Berhad (as of Nov 4, 2026): return on equity 5.2%, debt of 0.25 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 0332 from its 52-week high?
Topvision Eye Specialist Berhad trades at 0.1700 MYR, about 17% below its 52-week high of 0.2050 MYR and 13% above the low of 0.1500 MYR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 0.1500 MYR is for.
Which stocks are comparable to Topvision Eye Specialist Berhad?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Topvision Eye Specialist Berhad stock attractive at the current price?
The data as of Nov 4, 2026: price 0.1700 MYR, calculated fair value 0.1500 MYR (−12%), Quality Score 45/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0332 calculated?
We run Topvision Eye Specialist Berhad through 25 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 0.1500 MYR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Topvision Eye Specialist Berhad itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Topvision Eye Specialist Berhad (0332)?
The closing price on Nov 6, 2026 was 0.1700 MYR. Our model-based fair value is 0.1500 MYR, about 12% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Topvision Eye Specialist Berhad right now?
A fairly wide model range (0.0900 MYR to 0.2200 MYR) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Topvision Eye Specialist Berhad
How large is the market capitalisation of Topvision Eye Specialist Berhad (0332)?
The market capitalisation of Topvision Eye Specialist Berhad is 52.7M MYR (≈ $13.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Topvision Eye Specialist Berhad (0332)?
The price-to-sales ratio of Topvision Eye Specialist Berhad is 1.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Topvision Eye Specialist Berhad (0332)?
Earnings per share at Topvision Eye Specialist Berhad are 0.0100 MYR (price ÷ EPS = P/E 17.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Topvision Eye Specialist Berhad (0332)?
The dividend yield of Topvision Eye Specialist Berhad is 11.8% (payout 200%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Topvision Eye Specialist Berhad (0332)?
The net margin of Topvision Eye Specialist Berhad is 4.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Topvision Eye Specialist Berhad (0332)?
The return on equity (ROE) of Topvision Eye Specialist Berhad is 5.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Topvision Eye Specialist Berhad (0332)?
On an EBIT basis the return on assets of Topvision Eye Specialist Berhad is 12.2% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Topvision Eye Specialist Berhad (0332)?
The operating margin of Topvision Eye Specialist Berhad is 20.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Topvision Eye Specialist Berhad (0332)?
Revenue at Topvision Eye Specialist Berhad is growing +15.6% versus a year earlier (3y avg +5.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Topvision Eye Specialist Berhad (0332)?
Earnings per share at Topvision Eye Specialist Berhad are growing +182% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Topvision Eye Specialist Berhad (0332) carry?
The net debt of Topvision Eye Specialist Berhad is 1.1M MYR (fiscal year 2025, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Topvision Eye Specialist Berhad in the live analysis
One click puts Topvision Eye Specialist Berhad on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026